Table 4. Cox regression analysis of known prognostic markers and MAGE expression in the surgical cohort.
Factor | n | HR | 95% CI | p value | ||
---|---|---|---|---|---|---|
T | T1 | 157 | 1 | 1 | 1 | |
T2 | 155 | 2.401 | 1.582 | 3.643 | < 0.001 | |
T3 | 83 | 2.952 | 1.877 | 4.644 | < 0.001 | |
T4 | 41 | 2.965 | 1.734 | 5.070 | < 0.001 | |
T1 | 157 | 1 | 1 | 1 | ||
T2-4 | 279 | 2.651 | 1.815 | 3.873 | < 0.001 | |
T1-2 | 312 | 1 | 1 | 1 | ||
T3-4 | 124 | 1.829 | 1.335 | 2.507 | < 0.001 | |
T1-3 | 395 | 1 | 1 | 1 | ||
T4 | 41 | 1.594 | 1.016 | 2.500 | 0.042 | |
N | N0 | 236 | 1 | 1 | 1 | |
N1 | 66 | 1.856 | 1.199 | 2.873 | 0.006 | |
N2a | 16 | 1.103 | 0.444 | 2.738 | 0.833 | |
N2b | 79 | 2.633 | 1.774 | 3.908 | < 0.001 | |
N2c | 36 | 2.622 | 1.604 | 4.288 | < 0.001 | |
N3 | 3 | 1.325 | 0.184 | 9.550 | 0.780 | |
N0 | 233 | 1 | 1 | 1 | ||
N1 | 69 | 1.730 | 1.118 | 2.679 | 0.014 | |
N2 | 131 | 2.344 | 1.664 | 3.302 | < 0.001 | |
N3 | 3 | 1.308 | 0.181 | 9.429 | 0.790 | |
N0 | 233 | 1 | 1 | 1 | ||
N+ | 203 | 2.100 | 1.534 | 2.876 | < 0.001 | |
R | R0 | 326 | 1 | 1 | 1 | |
R1 | 30 | 1.466 | 0.828 | 2.597 | 0.190 | |
R2 | 4 | 2.056 | 0.507 | 8.333 | 0.313 | |
R0 | 326 | 1 | 1 | 1 | ||
R+ | 34 | 1.524 | 0.892 | 2.606 | 0.123 | |
L | L0 | 137 | 1 | 1 | 1 | |
L1 | 60 | 2.368 | 1.477 | 3.798 | < 0.001 | |
V | V0 | 173 | 1 | 1 | 1 | |
V1 | 14 | 1.848 | 0.843 | 4.052 | 0.125 | |
Grading | 1 | 18 | 1 | 1 | 1 | |
2 | 238 | 1.106 | 0.483 | 2.533 | 0.811 | |
3 | 112 | 1.409 | 0.604 | 3.285 | 0.427 | |
ECE | – | 109 | 1 | 1 | 1 | |
+ | 61 | 1.697 | 1.094 | 2.631 | 0.018 | |
HPV | HPV DNA − | 403 | 1 | 1 | 1 | |
HPV DNA + | 34 | 0.373 | 0.165 | 0.844 | 0.018 | |
HPV DNA–OR p16 − | 409 | 1 | 1 | 1 | ||
HPV + AND p16 + | 26 | 0.485 | 0.215 | 1.097 | 0.082 | |
Sex | female | 111 | 1 | 1 | 1 | |
male | 326 | 0.798 | 0.568 | 1.123 | 0.196 | |
Primary Site | Larynx | 142 | 1 | 1 | 1 | |
Oral Cavity | 110 | 3.213 | 2.09 | 4.940 | < 0.001 | |
Oropharynx | 134 | 2.044 | 1.327 | 3.148 | 0.001 | |
Hypopharynx | 51 | 1.748 | 0.984 | 3.105 | 0.057 | |
Smoking | Non-Smoker | 42 | 1 | 1 | 1 | |
Smoker | 300 | 1.109 | 0.61 | 2.018 | 0.734 | |
Non-smoker | 42 | 1 | 1 | 1 | ||
< = 10 py | 21 | 0.84 | 0.315 | 2.238 | 0.727 | |
> 10 < 20 | 40 | 0.781 | 0,337 | 1.808 | 0.564 | |
> 20 < 30 | 61 | 0.857 | 0.406 | 1.813 | 0.687 | |
> 30 < 40 | 62 | 0.88 | 0.423 | 1.827 | 0.731 | |
> 40 | 116 | 1.587 | 0.847 | 2.976 | 0.150 | |
Non-smoker | 42 | 1 | 1 | 1 | ||
< median (36) | 136 | 0.825 | 0.429 | 1.586 | 0.564 | |
> median (36) | 164 | 1.368 | 0.739 | 2.533 | 0.318 | |
Non-Smoker | 42 | 1 | 1 | 1 | ||
< 40 py | 137 | 0.818 | 0.425 | 1.572 | 0.547 | |
> = 40 py | 163 | 1.379 | 0.745 | 2.553 | 0.306 | |
pan-MAGE | negative | 202 | 1 | 1 | 1 | |
positive | 143 | 1.454 | 1.037 | 2.040 | 0.030 | |
negative | 202 | 1 | 1 | 1 | ||
cyt OR nuc | 73 | 1.354 | 0.883 | 2.075 | 0.165 | |
cyt + nuc | 70 | 1.556 | 1.034 | 2.343 | 0.034 | |
MEI < 0.1 | 238 | 1 | 1 | 1 | ||
MEI 0.1–0.39 | 72 | 1.001 | 0.654 | 1.533 | 0.995 | |
MEI 0.4–0.69 | 16 | 1.896 | 0.953 | 3.772 | 0.068 | |
MEI 0.7–1 | 9 | 1.513 | 0.614 | 3,729 | 0.368 | |
MAGE-A3/A4 | negative | 207 | 1 | 1 | 1 | |
positive | 139 | 1.511 | 1.077 | 2.119 | 0.017 | |
negative | 208 | 1 | 1 | 1 | ||
cyt OR nuc | 67 | 1.436 | 0.931 | 2.216 | 0.102 | |
cyt + nuc | 71 | 1.636 | 1.094 | 2.448 | 0.017 | |
MEI < 0.1 | 243 | 1 | 1 | 1 | ||
MEI 0.1–0.39 | 62 | 1.293 | 0.834 | 2.004 | 0.251 | |
MEI 0.4–0.69 | 21 | 1.244 | 0.646 | 2.393 | 0.514 | |
MEI 0.7–1 | 5 | 2.622 | 0.96 | 7.149 | 0.060 | |
MAGE-A1 | negative | 279 | 1 | 1 | 1 | |
positive | 67 | 0.853 | 0.565 | 1.288 | 0.450 |
The comparators for each variable are signified by a HR of 1.
Abbreviations: T = T-classification, N = N-classification, ECE = extracapsular extension, L = Lymphangiosis, V = vascular tumor emboli, R = resection margin status, HPV = human papilloma virus. n = absolute number of cases with available data, HR = hazard ratio, CI = confidence interval.